Several studies have shown that HDAC7 is dysregulated in many cancers, including nasopharyngeal carcinoma, gastric cancer, and glioma; this dysregulation is associated with metastasis and a poor prognosis and is the main target of several HDAC inhibitors (HDACis) [21–23]. This evidence concerns the gene HDAC7 and central nervous system cancer.